Axonics Modulation Technologies, Inc.
Formerly American Restorative Medicine, Inc.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2017 | $55 M | No. 4 | $50 to $250 million | equity | SEC | |
| Dec 2015 | $39 M | No. 3 | $10 to $50 million | equity | SEC | |
| Apr 2015 | $17 M | No. 2 | $10 to $50 million | equity | SEC | |
| Mar 2014 | $14 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Axonics Modulation Technologies, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2018).
SEC Form D · Apr 2018
The industry group it chose in its notices: Other Technology.
SEC Form D · Apr 2018
That is all the official record says: Axonics Modulation Technologies, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
15 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Advent Life Sciences Fund II LP | Fund or asset manager | not stated | not stated | Held Series B-2 and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Advent Life Sciences LLP | Fund or asset manager | not stated | not stated | Held Series B-2 and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Alfred E. Mann Foundation for Scientific Research | Other | not stated | not stated | Held Series A and B-1 preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Andera Partners | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2 and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series B-2 and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series B-2 and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Cormorant Private Healthcare Fund I, LP | Fund or asset manager | not stated | not stated | Held Series B-2 and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Gilde Healthcare Holding B.V. | Other | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Gilde Healthcare IV Management B.V. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Guangqiang Jiang | Person | not stated | not stated | Held Series B-1 preferred stock (Form 3, 2018) | SEC Form 3 |
| Longitude Capital Partners III, LLC | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Longitude Venture Partners III, L.P. | Venture capital | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| NeoMed Innovation V L.P. | Fund or asset manager | not stated | not stated | Held Series A, B-1, B-2 and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| NeoMed Innovation V Ltd | Company | not stated | not stated | Held Series A, B-1, B-2 and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Zac & Cloud Holdings LTD | Company | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 17 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Dan L. Dearen | Executive officer | Apr 2018 |
| Michael L. Williamson | Executive officer | Apr 2018 |
| Raymond W. Cohen | Executive officer | Apr 2018 |
| Michael V. Williamson | Executive officer | Mar 2014 |
| Erik L. Amble | Director | Apr 2018 |
| Geoff L. Pardo | Director | Apr 2018 |
| John L. Petrovich | Director | Apr 2018 |
| Juliet Tammenoms Bakker | Director | Apr 2018 |
| Raphael L. Wisniewski | Director | Apr 2018 |
| Raymond W. Cohen | Director | Apr 2018 |
| Shahzad L. Malik | Director | Apr 2018 |
| Darren L. Cai | Director | May 2017 |
| Farah L. Boroomand | Director | May 2017 |
| Barry L. Keenan | Director | Dec 2015 |
| David L. Hankin | Director | Apr 2015 |
| David V. Hankin | Director | Mar 2014 |
| John G. Petrovich | Director | Mar 2014 |
| Raphael V. Wisniewski | Director | Mar 2014 |
| Robert V. Guezuraga | Director | Mar 2014 |